Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) EBIT Margin (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of EBIT Margin data on record, last reported at 92991.67% in Q4 2025.

  • For Q4 2025, EBIT Margin rose 2849722.0% year-over-year to 92991.67%; the TTM value through Dec 2025 reached 512.91%, up 9850563.0%, while the annual FY2025 figure was 512.91%, 9850530.0% up from the prior year.
  • EBIT Margin reached 92991.67% in Q4 2025 per VRDN's latest filing, down from 56.7% in the prior quarter.
  • Across five years, EBIT Margin topped out at 56.7% in Q3 2025 and bottomed at 142356.0% in Q2 2025.
  • Average EBIT Margin over 5 years is 59249.63%, with a median of 72548.24% recorded in 2023.
  • Peak YoY movement for EBIT Margin: crashed -7077795bps in 2023, then skyrocketed 9701307bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 13589.25% in 2021, then crashed by -244bps to 46729.52% in 2022, then crashed by -112bps to 99275.0% in 2023, then fell by -22bps to 121488.89% in 2024, then increased by 23bps to 92991.67% in 2025.
  • Per Business Quant database, its latest 3 readings for EBIT Margin were 92991.67% in Q4 2025, 56.7% in Q3 2025, and 142356.0% in Q2 2025.